SEC Form 4 · accession 0001093557-17-000073
DEXCOM INC · DXCM
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Andrew K Balo
Officer — EVP, Clinical and Regulatory
Period of report
Mar 10, 2017
Accepted (ET)
Mar 14, 2017 · 7:57 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001093557
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2 | Mar 10, 2017 | S | 3,200 | $77.71 | D | 129,463 | D | |
| Common StockF3,F2 | Mar 10, 2017 | D | 3,528 | $77.5506 | D | 125,935 | D | |
| Common StockF3,F2 | Mar 10, 2017 | D | 6,694 | $77.5506 | D | 119,241 | D | |
| Common StockF3,F2 | Mar 10, 2017 | D | 3,208 | $77.5506 | D | 116,033 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1On December 09, 2016, Mr. Balo adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Balo. The shares set forth above were sold pursuant to the 10b5-1 Plan.
- F2Included in this number are 69,927 unvested restricted stock units, 28,761 of which were granted on March 8, 2017 and shall vest through March 8, 2020, 25,333 of which were granted on March 8, 2016 and shall vest through March 8, 2019 and 15,833 of which were granted on March 8, 2015 and shall vest through March 8, 2018.
- F3These shares were sold to cover the Company's tax withholding obligation that accrued in connection with the vesting of restricted stock units previously granted.